icad inc. Average Days of Payables

Average Days of Payables of ICAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Payables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Payables for 2020 was 160.09 (a 14.68% increase from previous year)
  • Annual Average Days of Payables for 2019 was 139.6 (a 162.91% increase from previous year)
  • Annual Average Days of Payables for 2018 was 53.1 (a 31.62% increase from previous year)
  • Twelve month Average Days of Payables ending March 30, 2021 was -15.08 (a -109.67% decrease compared to previous quarter)
  • Twelve month trailing Average Days of Payables decreased by -126.05% year-over-year
Trailing Average Days of Payables for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
-15.08 155.99 129.9 57.89
Visit stockrow.com/ICAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Payables of icad inc.

Most recent Average Days of Payablesof ICAD including historical data for past 10 years.

Interactive Chart of Average Days of Payables of icad inc.

icad inc. Average Days of Payables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 160.09
2019 139.6
2018 53.1
2017 40.34
2016 63.76
2015 47.64
2014 61.83
2013 73.13
2012 85.89
2011 50.7
2010 186.91

Business Profile of icad inc.

Sector: Healthcare
Industry: Health Information Services
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.